Skip to main content
Evidence Snapshot

Envelope glycoprotein gp160

CHEMBL1293311 SINGLE PROTEIN Human immunodeficiency virus 1
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T23:01:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1293311
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Envelope glycoprotein gp160 as ChEMBL target CHEMBL1293311, mapped to UniProt Q6QLK5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Envelope glycoprotein gp160
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-12
ChEMBL target ID
CHEMBL1293311
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
Q6QLK5
Envelope glycoprotein gp160
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Envelope glycoprotein gp160 matters

As of 2026-09-12

Envelope glycoprotein gp160 is reviewed as Envelope glycoprotein gp160 (UniProt Q6QLK5); Envelope glycoprotein gp160 shows clinical signal disease relevance led by AIDS. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 597 compounds, and 67 assays, with lead potency reaching pChEMBL 9.1.

Disease context
AIDS

Envelope glycoprotein gp160 shows clinical signal disease relevance led by AIDS. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include PRO-542.

Start review with AIDS because it currently carries clinical signal support. Linked drugs include PRO-542. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 597 compounds, and 67 assays for this target. The dominant activity type is IC50. CHEMBL3301620 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL3301620 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Envelope glycoprotein gp160 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q6QLK5, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why AIDS is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

597
Total Compounds
67
Total Assays
5
Approved Drugs
IC50: 566.0, KI: 34.0, EC50: 23.0, KD: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3301620
 9.1 Kd Clinical
No preferred name
CHEMBL4281745
 9.1 IC50 —
No preferred name
CHEMBL5204063
 8.8 IC50 —
No preferred name
CHEMBL4575700
 8.8 EC50 —
No preferred name
CHEMBL4644236
 8.6 IC50 —

Approved Drugs

Structure Compound First Approval
EFAVIRENZ
CHEMBL223228
 1998
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T23:01:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1293311